Document and Entity Information [Abstract] Document And Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Trading Symbol Trading Symbol Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Statement Of Financial Position [Abstract] Statement of Financial Position [Abstract] Statement [Table] Statement [Table] Statement [Line Items] Statement [Line Items] Statement [Line Items] Assets [Abstract] Assets Cash and Cash Equivalents, At Carrying Value Cash and cash equivalents Total Cash and cash equivalents at beginning of period CASH AND CASH EQUIVALENTS AT END OF PERIOD Prepaid Research and Development Prepaid research and development Sum of the amounts paid in advance for capitalized costs that will be expensed with Research and development. Other Assets, Current Other current assets Assets, Current Total current assets Total current assets Property, Plant and Equipment, Net Equipment, net In Process Research and Development In-process research and development Carrying amount as of the balance sheet date of non current portion of in-process research and development costs. Goodwill Goodwill Assets Total assets Total assets Liabilities and Equity [Abstract] Liabilities and equity Notes Payable, Current Notes payable, Current portion, net Notes payable, current portion Other Accounts Payable and Accrued Liabilities Accounts payable and accrued expenses Deferred Compensation Liability, Current Accrued compensation Deferred Revenue, Current Current portion of deferred revenue Interest Payable, Current Interest payable Liabilities, Current Total current liabilities Total current liabilities Deferred Revenue, Noncurrent Deferred revenue, net of current portion Notes Payable, Noncurrent Notes payable, Non-current portion, net Notes payable, noncurrent portion, at fair value Notes payable, noncurrent portion, at fair value Notes payable, less current portion, at fair value Liabilities Total liabilities Total liabilities Commitments and Contingencies Commitments and contingencies Stockholders Equity Attributable To Parent [Abstract] Equity: Preferred Stock, Value, Issued Preferred stock, $0.001 par value per share (10,000,000 shares authorized, 0 issued and outstanding as of March 31, 2013 and December 31, 2012) Common Stock, Value, Issued Common stock, $0.001 par value per share (500,000,000 shares authorized, 26,322,671 and 25,820,738 shares issued and outstanding at March 31, 2013 and December 31, 2012, respectively) Contingently Issuable Shares Contingently issuable shares The shares issuable for merger of companies Additional Paid In Capital Additional paid-in capital Treasury Stock, Value Treasury stock, at cost, [5,973] and 0 shares at December 31, 2012 and 2011, respectively Treasury stock, at cost, 13,526 shares at March 31, 2013 and December 31, 2012 Development Stage Enterprise, Deficit Accumulated During Development Stage Deficit accumulated in development stage Deficit accumulated in the development stage Stockholders' Equity, Including Portion Attributable To Noncontrolling Interest Balance Total equity Balance Balance Liabilities and Equity Total liabilities and equity Total liabilities and equity Preferred Stock, Par Or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Preferred Stock, Liquidation Preference, Value Preferred Stock, Liquidation Preference Per Share (in dollars) Common Stock, Par Or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common Stock, Shares Authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Treasury Stock, Shares Treasury stock Income Statement [Abstract] Income Statement [Abstract] Licenses Revenue Licenses Revenue License revenue License revenue Costs and Expenses [Abstract] Costs and expenses: Non Cash Stock Expense Noncash stock expense associated with in-licensing agreement The aggregate expense related to the issuance of stock in connection with in-licensing agreements during the reporting period. Non Cash Compensation Research and Development Expenses Non cash compensation The aggregate compensation expense related to the grants of stock options and restricted stock that is attributable to research and development expenses during the reporting period. Noncash compensation Other Research and Development Other research and development Other research and development expense during the period. Other research and development Research and Development Expense Total research and development Total research and development General and Administrative Expense [Abstract] General and administrative: Non Cash Compensation General and Administrative Expenses Noncash compensation The aggregate compensation expense related to the grants of stock options and restricted stock that is attributable to general and administrative expenses during the reporting period. Other General and Administrative Expense Other general and administrative General and Administrative Expense Total general and administrative Total general and administrative Impairment Of In Process Research And Development Impairment of in-process research and development Impairment of in-process research and development Impairment of in-process research and development Represents the impairment of in process research and development. Operating Expenses Total costs and expenses Total costs and expenses Operating Income (Loss) Operating loss Nonoperating Income (Expense) [Abstract] Other (income) expense: Investment Income, Net Interest income Interest income Interest income Other Income Other income Other income Other income Interest Expense Interest expense Interest expense Change In Fair Value Of Non Current Note Payable Change in fair value of notes payable The change in the fair value of non current notes payable recognized during the period. Change in fair value of notes payable Nonoperating Income (Expense) Total other income Total other income Total other (income) expense Total other (income) expense Total other (income) expense Income (Loss) From Continuing Operations Before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Loss before income taxes, as reported in the consolidated statements of operations Loss before income taxes Income Tax Expense (Benefit) Income taxes Income taxes Net Income (Loss), Including Portion Attributable To Noncontrolling Interest Loss before income taxes, as reported in the consolidated statements of operations Net loss Consolidated net loss Consolidated net loss Consolidated net loss Net Income (Loss) Attributable To Noncontrolling Interest Net loss attributable to non-controlling interest Net Income (Loss) Attributable To Parent Consolidated net loss, as reported in the consolidated statements of operations Net loss Net loss attributable to TG Therapeutics, Inc. and Subsidiaries Net loss attributable to TG Therapeutics, Inc. and subsidiaries Earnings Per Share, Basic and Diluted Basic and diluted net loss per common share (in dollars per share) Weighted Average Number Of Shares Outstanding, Basic and Diluted Weighted average shares used in computing basic and diluted net loss per common share (in shares) Statement Of Stockholders Equity [Abstract] Statement of Stockholders Equity [Abstract] Statement of Stockholders Equity [Abstract] Equity Components [Axis] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Restricted Common Stock [Member] Contingently Issuable Shares [Member] Additional Paid-In Capital [Member] Treasury Stock [Member] Accumulated Deficit During Development Stage [Member] Non Controlling Interest In Subsidiary [Member] Non-Controlling Interest In Subsidiary [Member] Equity Component [Domain] Equity Component [Domain] Compensation [Axis] Compensation [Axis] Compensation [Domain] Compensation [Domain] Restricted Preferred Stock [Member] Restricted Common Stock [Member] Shares, Outstanding Balance Balance (in shares) Balance (in shares) Stock Issued During Period Value, Exercise Of Warrants Issuance of common stock in connection with exercise of warrants Represents the value of stock issued during the period due to the exercise of warrants. Stock Issued During Period Shares, Exercise Of Warrants Issuance of common stock in connection with exercise of warrants (in shares) Represents the number of shares of stock issued during the period due to the exercise of warrants. Stock Issued During Period, Value, Restricted Stock Award, Gross Issuance of restricted stock Stock Issued During Period, Shares, Restricted Stock Award, Gross Issuance of restricted stock (in shares) Adjustments To Additional Paid In Capital, Share-Based Compensation, Stock Options, Requisite Service Period Recognition Compensation in respect of restricted stock granted to employees, directors and consultants Compensation in respect of restricted stock granted to employees, directors and consultants Statement Of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Net Cash Provided By (Used In) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract] Adjustments to reconcile consolidated net loss to cash used in operating activities: Share-Based Compensation Stock-based compensation expense associated with restricted stock Stock compensation expense Shares Issued In Connection With In Licensing Agreement Noncash stock expense associated with in-licensing agreement Value of common stock issued during the period in exchange for license agreement. Depreciation Depreciation Change In Fair Value Of Notes Payable Change in fair value and accrued interest of notes payable The change in fair value of notes payable during the period. Change in fair value and accrued interest of notes payable Increase (Decrease) In Operating Capital [Abstract] Changes in assets and liabilities, net of effects of acquisition: Increase (Decrease) In Other Current Assets (Increase) decrease in other current assets (Increase) decrease in other current assets Increase (Decrease) In Other Accounts Payable and Accrued Liabilities Increase (Decrease) in accounts payable and accrued expenses Increase (Decrease) In Interest Payable, Net Increase in interest payable Increase (Decrease) In Deferred Revenue (Decrease) increase in deferred revenue Net Cash Provided By (Used In) Operating Activities Net cash used in operating activities Net cash used in operating activities Net Cash Provided By (Used In) Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES CASH FLOWS FROM INVESTING ACTIVITIES Payments To Acquire Property, Plant, and Equipment Purchases of property, plant and equipment Purchases of property, plant and equipment Cash Acquired From Acquisition Cash acquired in connection with acquisition Net Cash Provided By (Used In) Investing Activities Net cash provided by investing activities Net cash provided by investing activities Net Cash Provided By (Used In) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES CASH FLOWS FROM FINANCING ACTIVITIES Proceeds From Warrant Exercises Proceeds from the exercise of warrants Repayments Of Short-Term Debt Payments of short-term loans Payments of short-term loans Proceeds From Issuance Of Common Stock Proceeds from sale of common stock, net Proceeds From Issuance Of Preferred Stock and Preference Stock Proceeds from sale of preferred stock, net Payments Of Stock Issuance Costs Offering costs paid Offering costs paid Payments for Repurchase of Common Stock Purchase of treasury stock Purchase of treasury stock Net Cash Provided By (Used In) Financing Activities Net cash provided by financing activities Net cash provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease) NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS Nonmonetary Transactions [Abstract] NONCASH TRANSACTIONS Conversion Of Notes Payable To Preferred Stock Conversion of notes payable to preferred stock Conversion Of Notes Payable To Preferred Stock during the year. Accrued Financing Costs Accrued financing costs Accrued Financing Costs during the period. Organization, Consolidation and Presentation Of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation Of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Significant Accounting Policies [Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value Disclosures [Text Block] Stockholders' Equity Note [Abstract] Stockholders Equity Note [Abstract] Shareholders' Equity and Share-Based Payments [Text Block] Stockholders Equity Note Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Debt Disclosure [Text Block] Debt Disclosure [Text Block] License Agreement Abstract LicenseAgreement [Abstract] License Agreement Disclosure [Text Block] License Agreement Disclosure [Text Block] The entire disclosure for research, development, and License Agreement activities, including contracts and arrangements to be performed for others and with federal government. Related Party Transactions [Abstract] Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] Related Party Transactions Disclosure [Text Block] Accounting Policies [Abstract] Accounting Policies [Abstract] Business Description [Policy Text Block] Business Description [Policy Text Block] Reflects the description of business of the entity. Correction Of Immaterial Error [Policy Text Block] Correction Of Immaterial Error [Policy Text Block] Disclosure of accounting policy for correction of an immaterial error. Liquidity Disclosure [Policy Text Block] Liquidity Disclosure [Policy Text Block] Management Changes [Policy Text Block] 2011 Management Changes [Policy Text Block] Represents the disclosure of management changes. New Accounting Pronouncements, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Basis Of Accounting, Policy [Policy Text Block] Basis of Accounting, Policy [Policy Text Block] Use Of Estimates, Policy [Policy Text Block] Use of Estimates, Policy [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Revenue Recognition, Policy [Policy Text Block] Revenue Recognition, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] In Process Research and Development, Policy [Policy Text Block] In Process Research and Development, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Share-Based Compensation, Option and Incentive Plans Policy [Policy Text Block] Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Earnings Per Share, Policy [Policy Text Block] Earnings Per Share, Policy [Policy Text Block] Impairment Of Tangible and Intangible Asset Including Goodwill [Policy Text Block] Impairment Of Tangible and Intangible Asset Including Goodwill [Policy Text Block] Disclosure related to policy for impairment of tangible and intangible asset including goodwill. Fair Value, Liabilities Measured On Recurring and Nonrecurring Basis [Table Text Block] Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis [Table Text Block] Fair Value, Liabilities Measured On Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Change In Level Three Fair Value During Period [Table Text Block] Fair Value Measurements, Nonrecurring [Table Text Block] Fair Value Measurements, Nonrecurring [Table Text Block] Preferred Restricted Stock [Member] Common Restricted Stock [Member] Schedule Of Share-Based Compensation, Stock Options, Activity [Table Text Block] Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule Of Nonvested Restricted Stock Units Activity [Table Text Block] Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Schedule Of Warrants Activity [Table Text Block] Schedule Of Warrants Activity [Table Text Block] Tabular disclosure for warrants activity. Schedule Of Share Based Compensation Expense [Table Text Block] Schedule Of Share Based Compensation Expense [Table Text Block] Tabular disclosure of share based compensation expense. Schedule Of Debt [Table Text Block] Schedule of Debt [Table Text Block] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Opus Point Partners, Llc [Member] Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period. Tg Bio [Member] Private Placement [Member] Class Of Stock [Axis] Class of Stock [Axis] Class Of Stock [Domain] Class of Stock [Domain] Series Preferred Stock [Member] Restricted Series A Preferred [Member] Deferred Bonus and Profit Sharing Plan By Title Of Individual [Axis] Deferred Bonus and Profit Sharing Plan by Title of Individual [Axis] Title Of Individual With Relationship To Entity [Domain] Title of Individual with Relationship to Entity [Domain] Michael S.Weiss [Member] One of the ranking officers of the entity, appointed to the position by the board of directors. Sean Power [Member] Base salary under employment agreement. Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Mr Power [Member] Mr.Power [Member] Mr Weiss [Member] Mr.Weiss [Member] Vesting Period [Axis] Vesting Period [Axis] Represents vesting Period Vesting Period [Domain] Vesting Period [Domain] Represents vesting Period. November 15, 2012 [Member] November 15, 2012. November 15, 2013 [Member] Year One [Member] November 15, 2013. November 15, 2014 [Member] Year Two [Member] November 15, 2014. November 15, 2015 [Member] Year Three [Member] November 15, 2015. Market Capitalization Target [Axis] Market Capitalization Target [Axis] Represents Market capitalization target. Market Capitalization Target [Domain] Market Capitalization Target [Domain] Represents Market capitalization target Market Capitalization Target One [Member] Represents Market capitalization target Market Capitalization Target Two [Member] Represents Market capitalization target Immaterial Error [Axis] Immaterial Error [Axis] Represents immaterial error. Immaterial Error [Domain] Immaterial Error [Domain] Before Correction Of Immaterial Error [Member] After Correction Of Immaterial Error [Member] Business Acquisition, Equity Interest Issued Or Issuable, Number Of Shares Number of shares of Manhattan common stock outstanding at the time of the transaction Convertible Preferred Stock, Shares Issued Upon Conversion Convertible Preferred Stock, Shares Issued upon Conversion Placement Agent Commision Description Placement Agent Commision Description Refelcts the disclosure of commision paid to placement agent. Professional Fees Professional Fees Payments Of Placement Agent Commisions Payments Of Placement Agent Commisions Represents the amount of placement agent commisions incurred inrelation to the issue. Compensation Compensation Percentage Of Reduction In Salary Upon Resignationfrom Interim Roles Percentage Of Reduction In Salary Upon Resignation from Interim Roles Represents the percentage of reduction in base salary upon resignation from interim roles. Percentage Of Outstanding Shares Granted Annually Percentage Of Outstanding Shares Granted Annually Represents the percentage of shares outstanding granted annually. Percentage Of Annual Grants Restricted Stock That Will Vest and Become Nonforfeitable On First Anniversary Percentage Of Annual Grants Restricted Stock Becoming Non Forfeitable On First Aniversary Percentage of annual grants of restricted stock that will vest and become non-forfeitable on first aniversary. Percentage Of Annual Grants Restricted Stock That Will Vest and Become Nonforfeitable On Second Aniversary Percentage Of Annual Grants Restricted Stock That Will Vest And Become Nonforfeitable On Second Aniversary Percentage of annual grants restricted stock that will vest and become nonforfeitable on second aniversary. Market Capitalization Increase To Trigger Restricted Stock That Will Vest and Become Nonforfeitable Market Capitalization Increase To Trigger Restricted Stock That Will Vest And Become Nonforfeitable Amount of increase in market capitalization from date of grant to trigger restricted stock that will vest and become non-forfeitable. Percentage Of Restricted Stock That Will Vest and Become Nonforfeitable Upon Market Capitalization Increase Percentage Of Restricted Stock That Will Vest And Become Nonforfeitable Upon Market Capitalization Increase Percentage of restricted stock that will vest and become nonforfeitable upon market capitalization increase. Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Percentage Of Stock Issued After Exchange Transaction Percentage Of Stock Issued After Exchange Transaction Represents Percentage of stock issued after exchange transaction Number Of Shares Vesting Schedule Number Of Shares Vesting Schedule Number of shares vesting schedule at the end of period. Business Acquisition Shares Not Surrendered Business acquisition shares not surrendered Reflects the number of shares not surrendered for repurchase as per the business acquisition agreement. Business Acquisition Shares Repurchased Percentage Business Acquisition Shares Repurchased Percentage Represents the approximate percentage the Company Preferred Stock issued at the time of the Exchange Transaction represented of the Company's outstanding voting stock. Research and Development In Process Research and Development in Process Period Anticipated Sufficient To Fund Operating Cash Flow Period Anticipated Sufficient To Fund Operating Cash Flow Disclosure about period anticipated sufficient to fund operating cash flow. Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period Warrants,Issued Number of Shares, Granted Stockholders' Equity, Reverse Stock Split Stockholders' Equity, Reverse Stock Split Decrease To Total Assets and Liabilities Decrease To Total Assets And Liabilities Decrease to total assets and liabilities. Cash Equivalents Maturity Period Cash Equivalents Maturity Period Reflects the policy for maturity period of liquid investments. Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Short-Term Debt, Type [Axis] Short-term Debt, Type [Axis] Short-Term Debt, Type [Domain] Short-term Debt, Type [Domain] Convertible Notes Payable [Member] Liabilities, Fair Value Disclosure Liabilities, Fair Value Disclosure 5% Notes Notes Payable, Fair Value Disclosure Notes Payable, Fair Value Disclosure Totals Fair Value, Measurement With Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Balance at December 31, 2011 Fair value at December 31, 2012 Fair value at March 31, 2013 Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Interest Accrued Included In Earnings Interest accrued on face value of 5% Notes Amount of interest recognized during the period, arising from liabilities measured at fair value on a recurring basis using unobservable inputs (level 3). Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) Change in fair value of Level 3 liabilities Type Of Transaction [Axis] Type Of Transaction [Axis] Type Of Transaction [Domain] Type Of Transaction [Domain] Manhattan and Ariston Pharmaceuticals Merger [Member] Component Of Other Operating Cost and Expense [Axis] Component of Other Operating Cost and Expense [Axis] Component Of Other Operating Cost and Expense, Name [Domain] Component of Other Operating Cost and Expense, Name [Domain] Nonrecurring [Member] nonrecurring Notes Issued Notes Issued Debt Instrument Maturity Period Debt Instrument Maturity Period Period when the debt instrument is scheduled to be fully repaid. Debt Instrument, Interest Rate, Effective Percentage Debt Instrument, Interest Rate, Effective Percentage Debt Instrument, Convertible, Conversion Price Debt Instrument, Convertible, Conversion Price Percentage Of Cash Proceeds From Operation To Repay Convertible Debt Percentage Of Cash Proceeds From Operation To Repay Convertible Debt Reflects level of percentage of net product cash flow received from the exploitation or commercialization of certain product candidates to repay certain convertible debt. Long-Term Debt, Gross Long-term Debt, Gross Debt Instrument, Fair Value Disclosure Debt Instrument, Fair Value Disclosure Fair Value Inputs, Discount Rate Fair Value Inputs, Discount Rate Repayments Of Long-Term Debt Repayments of Long-term Debt Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number Outstanding at January 1, 2011 Number of shares, Outstanding at December 31, 2012 Number of shares, Outstanding at March 31, 2013 Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Net Of Forfeitures Number of shares, Granted Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercises In Period Number of shares, Exercised Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period Number of shares, Forfeited Number of shares, Forfeited Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Expirations In Period Number of shares, Expired Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Number Number of shares, Vested and expected to vest at March 31, 2013 Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number Number of shares, Exercisable at March 31, 2013 Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance Outstanding at January 1, 2011 Weighted-average exercise price, Outstanding at December 31, 2012 Weighted-average exercise price, Outstanding at March 31, 2013 Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price Weighted-average exercise price, Granted Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Exercises In Period, Weighted Average Exercise Price Weighted-average exercise price, Exercised Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Forfeitures In Period, Weighted Average Exercise Price Weighted-average exercise price, Forfeited Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Expirations In Period, Weighted Average Exercise Price Weighted-average exercise price, Expired Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Weighted Average Exercise Price Weighted-average exercise price, Vested and expected to vest at March 31, 2013 Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted-average exercise price, Exercisable at March 31, 2013 Shares Based Compensation Arrangement By Shares Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term Weighted-average contractual Term, Outstanding at December 31, 2012 Weighted average remaining contractual term for option award outstanding. Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted-average contractual Term, Outstanding at March 31, 2013 Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Weighted Average Remaining Contractual Term Weighted-average contractual Term, Vested and expected to vest at March 31, 2013 Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted-average contractual Term, Exercisable at March 31, 2013 Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Intrinsic Value Outstanding at December 31, 2011 Aggregate Intrinsic Value, Outstanding Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Aggregate Intrinsic Value Aggregate Intrinsic Value, Vested and expected to vest at March 31, 2013 Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Intrinsic Value Aggregate Intrinsic Value, Exercisable at March 31, 2013 Outstanding at December 31, 2011 Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] Restricted Stock [Member] Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Number Outstanding at January 1, 2011 Outstanding at January 1, 2011 Number of Shares, Outstanding at December 31, 2012 Number of Shares, Outstanding at March 31, 2013 Number of Shares Restricted Series A Preferred Stock,Outstanding Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested In Period Warrants,Exercised Number of Shares, Vested Number of Shares, Vested Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Forfeited In Period Warrants,Expired Number of Shares, Forfeited Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance Weighted Average exercise price,Outstanding Outstanding at January 1, 2011 Weighted Average Grant Date Fair Value, Outstanding at December 31, 2012 Weighted Average Grant Date Fair Value, Outstanding at March 31, 2013 Weighted Average exercise price,Outstanding Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period, Weighted Average Grant Date Fair Value Weighted Average exercise price, Issued Number of Shares Restricted Series A Preferred Stock,Granted Weighted Average Grant Date Fair Value, Granted Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested In Period, Weighted Average Grant Date Fair Value Weighted Average exercise price,Exercised Vested Weighted Average Grant Date Fair Value, Vested Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted Average exercise price,Expired Forfeited Weighted Average Grant Date Fair Value, Forfeited Class Of Warrant Or Right, Outstanding Class of Warrant or Right, Outstanding Warrants, Outstanding at December 31, 2012 Warrants, Outstanding at March 31, 2013 Warrants Or Rights Assumed In Exchange Transaction Warrants Assumed in Exchange Transaction Represents the number of warrants assumed in exchange transaction. Warrant Or Right Issued Warrants, Issued Reflects the number of warrants issued during the period. Warrant Or Right Expired Warrants, Expired Reflects the number of warrants expired during the period. Warrant Or Right Outstanding Weighted Average Exercise Price Class Of Warrant Or Right Outstanding Weighted Average Exercise Price Weighted - average exercise price of Warrants, Outstanding at December 31, 2012 Weighted - average exercise price of Warrants, Outstanding at March 31, 2013 Reflects the weighted average exercise price of warrants outstanding. Warrants Or Rights Assumed In Exchange Transaction Weighted Average Exercise Price Weighted - average exercise price of Warrants Assumed in Exchange Transaction Reflects the weighted average exercise price of warrants assumed in exchange transaction. Warrant Or Right Issued Weighted Average Exercise Price Weighted - average exercise price of Warrants, Issued Reflects the weighted average exercise price of warrants issued. Warrant Or Right Exercised Weighted Average Exercise Price Weighted - average exercise price of Warrants, Exercised Reflects the weighted average exercise price of warrants Exercised. Warrant Or Right Expired Weighted Average Exercise Price Weighted - average exercise price of Warrants, Expired Reflects the weighted average exercise price of warrants Expired. Warrant Or Right Aggregate Intrinsic Value Class Of Warrant Or Right Aggregate Intrinsic Value Aggregate Intrinsic Value of Warrants, Outstanding Reflects the aggregate intrinsic value of warrants outstanding. Stock Options [Member] Restricted Stock Or Unit Expense Stock-based compensation expense associated with restricted stock Stock Or Unit Option Plan Expense Stock-based compensation expense associated with option grants Stock Option Plan [Member] 2012 Stock Option Plan [Member] Stock Option Plan 1995 [Member] 1995 Stock Option Plan [Member] granting of stock option in the year 1995 Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Two Thousand Twelve Issuance [Member] Incentive Plan [Member] 2012 Incentive Plan [Member] represents incentives plan of 2012 Equity Pipe 2011 [Member] Equity PIPE 2011 Equity Incentive Plans [Member] Chief Financial Officer [Member] Lfb [Member] Prior To Execution Of Securities Exchange Agreement [Member] relates execution of securities exchange member. Subsidiary, Sale Of Stock [Axis] Subsidiary, Sale of Stock [Axis] Sale Of Stock, Name Of Transaction [Domain] Sale of Stock, Name of Transaction [Domain] Placement Agent [Member] represents private placement agency Corporate Milestone [Axis] Corporate Milestone [Domain] Corporate Milestone [Member] Non Employee Stock Options [Axis] Non Employee Stock Optins [Axis] Non Employee Stock Options [Domain] Non Employee Stock Optins [Domain] Non Employee Stock Options [Member] Non Employee Restricted Stock [Member] represents restricted shares outstanding issued to non-employees Issuance Period [Axis] Issuance Period [Axis] Issuance Period [Domain] Issuance Period [Domain] Two Thousand Eleven Issuance [Member] Convertible Preferred Stock Share Converted Into Common Stock Convertible Preferred Stock Share Converted In Restricted Common Stock The number of shares of Common Stock the Company Preferred Stock is convertible into. Conversion Of Stock, Shares Converted Conversion of preferred stock to common stock in conjunction with reverse stock split (in shares) Converted preferred stock Converted Shares Conversion Of Stock, Shares Issued Conversion of Stock, Shares Issued Conversion of Stock, Shares Issued Stock Issued During Period, Shares, New Issues Effect of reverse acquisition (in shares) Stock issued, net of expenses (in shares) Stock Issued During Period Share Snew Issues Issue Price Stock Issued During Period Shares new Issues Issue Price Stock Issued During Period Share Snew Issues Issue Price The share issued price per unit. Fair Value Per Share Issued Fair Value Per Share Issued Reflects the fair value of share issued during the period. Proceeds From Issuance Of Private Placement Proceeds from Issuance of Private Placement Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights Class of Warrant or Right, Number of Securities Called by Warrants or Rights Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights Class of Warrant or Right, Exercise Price of Warrants or Rights Class Of Warrant Or Rights Exercisable Period Class Of Warrant Or Rights Exercisable Period Reflects the excercisable period of warrants. Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Available For Grant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Agent Cash Commission Percentage On Proceeds From Shares Issuance Agent Cash Commission Percentage On Proceeds From Shares Issuance The actual commision percentage given to the agent. Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Yet To Be Recognized Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Yet To Be Recognized As of the balance sheet date, the aggregate unrecognized cost of equity-based awards made to employees under equity-based compensation awards that have yet to be vested. Employee Service Share-Based Compensation, Nonvested Awards, Total Compensation Cost Not Yet Recognized, Period For Recognition Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition Employee Service Share-Based Compensation, Nonvested Awards, Total Compensation Cost Not Yet Recognized Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized Preferred Stock To Common Stock Conversion Basis Per Share Preferred Stock To Common Stock Conversion Basis Per Share Preferred stock to common stock conversion basis per share Share Based Compensation Non Employee Stock Options Outstanding Share Based Compensation Non Employee Stock Options Outstanding Share Based Compensation Non Employee Stock Options Outstanding. Employee Service Share Based Compensation Nonvested Award Total Compensation Cost Yet To Be Recognized Employee Service Share Based Compensation Nonvested Award Total Compensation Cost Yet To Be Recognized equity-based awards made to employees under equity-based compensation awards that have yet to be vested. Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Outstanding Number Outstanding at January 1, 2011 Number of shares, Outstanding Number of shares, Outstanding The number of stock, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Share Based Compensation Arrangement By Share Based Payment Award Options Maximum Term Share Based Compensation Arrangement By Share Based Payment Award Options Maximum Term The maximum term for the options. Share Based Compensation Arrangement By Share Based Payment Award Options Issued Share Based Compensation Arrangement By Share Based Payment Award Options Issued The number of shares issued under the stock options plan. Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Equity Method Investments Equity Method Investments Equity Method Investment, Ownership Percentage Equity Method Investment, Ownership Percentage Common Stock Pivate Placement Common Stock Pivate Placement Common stock issued in private placement. Percentage Of Gross Proceeds From Offering As Allowance For Non Accountable Expenses Of Placement Agents Percentage Of Gross Proceeds From Offering As Allowance For Non Accountable Expenses Of Placement Agents The percentage of the gross proceeds from the offering that the placement agents are allowed under non accountable expenses. Preferred Stock, Liquidation Preference Per Share Preferred Stock, Liquidation Preference Per Share Surrender Of Common Stock Surrender of common stock for tax withholding (in shares) Represents the number of shares surrendered. Warrants Exercised Either By Placement Agent Or Warrants Issued Warrants Exercised Either By Placement Agent Or Warrants Issued warrants exercised during the period. Preferred Stock Converted Into Common Stock Prior To Conversion Preferred Stock Converted Into Common Stock Prior To Conversion The number of shares of Common Stock the Company Preferred Stock is convertible into. Warrant Term Warrant Term Term of warrants received by placement agent. Agent Warrant Percentage On Issuance Of Shares Agent Warrant Percentage On Issuance Of Shares Reflects the percentage of agent warrant percentage on issuance of shares Agent Non Accountable Expense Percentage On Gross Proceeds From Share Issuance Agent Non Accountable Expense Percentage On Gross Proceeds From Share Issuance Reflects the percentage of agent non accountable expense percentage on gross proceeds from share issuance Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Noninterestbearing [Member] Non - Interest Bearing [Member] Convertible Notes [Member] Icon Convertible Notes [Member] ICON Convertible Notes [Member] Notes Payable Total Total Amendment [Axis] Amendment [Axis] amendement of business Amendment [Domain] Amendment [Domain] amendment domain Before Amendment [Member] business amendment After Amendment [Member] amendemnt of business after certain period Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Exchange Transaction [Member] Swiss Pharma [Member] Ariston [Member] Icon Clinical Research [Member] represents a member in connection with business. Manhattan [Member] Settlement Agreement Payment Business Acquisition, Cost of Acquired Entity, Cash Paid Represents the amount paid on behalf of settlement agreement. Waiver Period Waiver Period Represents the interest and principal period waiver months. Promissory Note Issued Promissory Note Issued Reflects the principal amount of a non-interest bearing promissory note issued. Debt Instrument Renegotiated Price Debt Instrument Renegotiated Price Reflects the debt instrument renegotiated price towards the period. Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Percentage Of Cash Proceeds From Operation To Repay Interest On Convertible Debt Percentage Of Cash Proceeds From Operation To Repay Interest On Convertible Debt Reflects level of percentage of net product cash flow received from the exploitation or commercialization of certain product candidates to repay certain convertible debt. Accounts Payable Accounts Payable Debt Instrument, Periodic Payment, Principal Debt Instrument, Periodic Payment, Principal One Time Settlement Amount For Waiver Of Interest and Principal Payments One Time Settlement Amount For Waiver Of Interest and Principal Payments Reflects the one time settlement amount paid by the entity for waiver of the interest and principal payments due. Interest and Debt Expense Interest and Debt Expense Interest Payable Interest Payable Debt Instrument Repayment Term Debt Instrument Repayment Term Represents the principle repayment period. Waiver Period Interest and Principal Waiver Period Interest and Principal Represents the interest and principal period waiver months. Business Combination Debt Instrument Amedment Description Business Combination Debt Instrument Amedment Description Represents the amedments to the debt instrument made in connection with the business combinations. Debt Instrument, Maturity Date Debt Instrument, Maturity Date Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Lfb Biotechnologies [Member] Collaboration Agreement [Member] Reflects agreemnet collaboration of the company Stock Issued During Period Shares License Option Stock Issued During Period Shares License Option Reflects the number of shares issued by the entity for acquiring the license option. Possible Milestone Payments Business Development Reflects the aggregate amount of possible milestone payments the Company may need to make upon successful achievement of certain milestones. Bussiness Acquisiton Purchase Agreement Period Description Bussiness Acquisiton Purchase Agreement Period Description Discloses the periodicity of the license agreement. Sale Of Stock, Number Of Shares Issued In Transaction Sale of Stock, Number of Shares Issued in Transaction Contribution Per Licence Agreement In Exchange Of Common Stock Common Stock Value Subscribed Subsidiary Sale Of Stock Reflects the contribution made by the Company to its subsidiary in exchange for common stock. Common Stock Shares Subscribed Subsidiary Sale Of Stock Common Stock Shares Subscribed Subsidiary Sale Of Stock Refelcts the number of shares subscribed by the entity on the issuance by its subsidiary. Shares Issued For Licence Agreement Exchange Subsidiary Shares Conversion Shares To Be Issued Reflects the numbers of shares common stock issued by the subsidiary, per the license agreement, that have the option of being converted to the Company's common stock. Payments Towards License Payments Towards License flects the amount paid towards licence Noncontrolling Interest, Description Noncontrolling Interest, Description Potential Royalty Payment Potential Royalty Payment Reflects the potential amount of payment to be made as royalty. Milestone Payment Milestone Payment Reflects the amount of milestone payment during the period. Potential Future Milestone Payments Potential future milestone payments Potential Future Milestone Payments Represents the potential future milestone payments the Company may have to make upon achievement of certain milestones. License and Maintenance Revenue License and Maintenance Revenue Deferred Revenue Deferred Revenue Additional Amount Receivable On Achievement Of Pre Specified Milestones Additional Amount Receivable On Achievement Of Pre Specified Milestones Reflects potential milestone payments to be received upon achievement of pre-specified milestone. Potential Additional Amount Payable On Achievement Of Pre Specified Milestones Aggregate Additional Amount Receivable On Achievement Of Pre Specified Milestones Reflects potential amount payable upon certain clinical development, regulatory, and sales based milestones in addition to royalties on net sales of certain drug products. Incremental Common Share Attributable To Security Exchange Agreement Incremental Common Share Attributable To Security Exchange Agreement Incremental common share attributable to Security exchange agreement. Board Of Directors Chairman [Member] Placement Agency Agreement [Axis] Placement Agency Agreement [Axis] Represents Placement Agency Agreement Placement Agency Agreement [Domain] Placement Agency Agreement [Domain] Represents Placement Agency Agreement. Lfb Group [Member] Placement Agency Agreement [Member] Represents Placement Agency Agreement. Rhizen [Member] Research Development Expenses [Axis] Research Development Expenses [Axis] Research Development Expenses [Domain] Research Development Expenses [Domain] Research Development Expenses [Member] Opus [Member] National Holdings [Member] Legal Expenses Reimbursed To Agent Legal Expenses Reimbursed To Agent Reflects the percentage of agent warrant percentage on issuance of shares. Advisory Fees Expenses Private Placement Advisory Fees Expenses Private Placement Reflects the amount of advisory fees paid towards the private placement agent Warrant Or Right Exercised Reflects the number of warrants exercised during the period. Warrants, Exercised Upfront Licenses Revenue Payment Received Upfront license revenue payment received from sublicense agreement. Upfront Fee Received From Sub License Upfront Licenses Revenue Payment Received Stock Option [Member] Number Of Common Stock Shares Granted In Connection With License Agreement By Issue Of Warrants Number of common shares granted in connection with license agreement by issue of warrants during the reporting period.